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BACKGROUND: It has been suggested that adjustment for incomplete compliance with follow-up in women with positive human
papillomavirus (HPV) tests would be appropriate for estimating the true sensitivity of cervical screening with HPV testing.
We assessed the compliance and its impact on XCIN3 detection in all eight randomised controlled trials (RCT) with published
baseline-round data.
METHODS: We extracted data on recommended follow-up procedures, follow-up compliance, and XCIN3 detection for both arms of
each RCT, and assessed their correlation.
RESULTS: Compliance with a direct referral for colposcopy was around 90% in all RCTs, whereas compliance with repeated testing
among HPV-positive/cytology-negative women was around 60% in three RCTs and 73% in one RCT. Detection of XCIN3 was
significantly increased in two out of six RCTs with reported data. The correlation between compliance with follow-up in HPV-positive
women and relative XCIN3 detection was 0.48 (P¼0.33).
CONCLUSION: There is at present scant evidence to support the view that the measured sensitivity of HPV screening is a simple
reflection of compliance with follow-up. Adjustment of measured cervical intraepithelial neoplasia detection on the basis of
compliance data may not always be justifiable, and if adjustment is made, it should be used very judiciously.
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Organised screening programmes using cytological testing are
proven to reduce both the incidence of and the mortality from
cervical cancer. However, screening with this method is needed
every 3–5 years, and even then the disease is not completely
eradicated in screened women (IARC, 2005). Human papilloma-
virus (HPV) DNA screening seems to be an attractive alternative to
cytology screening. This was first supported by split sample studies
in which more high-grade cervical intraepithelial neoplasia (CIN)
was detected with HPV DNA screening than with cytology
screening (Cuzick et al, 2008). Similar findings came from some
of the randomised controlled trials (RCT), for example, from the
Netherlands where HPV DNA screening detected 70% more
CIN3þ lesions than cytology screening (Bulkmans et al, 2007).
However, in recently published data from the ARTISTIC RCT
undertaken in the United Kingdom (Kitchener et al, 2009a),
the detection rate of CIN3þ lesions in the intervention arm
(HPV testing combined with liquid-based cytology) was similar to
that in the control arm (liquid-based cytology) (RR 0.97; 95%
confidence interval (CI, 0.75–1.25). This observation was attrib-
uted to incomplete ascertainment of cases by observing that only
41.2% of HPV-positive/cytology-negative (HPVþ/cyt ) women
were ‘properly investigated’ (Sasieni et al, 2009). By correcting
the observed CIN2þ detection for incomplete ascertainment, the
sensitivity of HPV screening became higher than that for cytology,
94 vs 84%. Therefore, compliance with follow-up among women
with positive screening tests needs to be carefully scrutinised to
make an adequate comparison of the sensitivity of HPV testing
measured in different trials.
In this paper, we present a thorough standardised overview
regarding compliance with follow-up for all eight RCTs, with
reported data from the baseline screening round. All of these RCTs
aimed at measuring the sensitivity of HPV screening as compared
with cytology screening, but women with positive screening tests
were nevertheless recommended varying follow-up procedures.
We therefore investigated the impact of the recommended follow-up
procedure on the completeness of follow-up of screen-positive
women, and subsequently assessed the effect of the completeness
of follow-up on the measured sensitivity of HPV screening.
MATERIALS AND METHODS
Eight RCTs comparing HPV DNA cervical screening with cytology
screening had their baseline-round data published by February
2010. Six of these RCTs were undertaken in Europe (two in Italy,
and one each in the Netherlands, United Kingdom, Sweden,
and Finland), one in Canada, and one in India (Elfgren et al, 2005;
Ronco et al, 2006a,b, 2008, 2010; Bulkmans et al, 2007; Mayrand
et al, 2007; Naucler et al, 2007, 2009; Kotaniemi-Talonen et al,
2008a,b; Leinonen et al, 2009; Sankaranarayanan et al, 2009;
Kitchener et al, 2009a,b). From these publications, we extracted
the data on the recommended follow-up procedure for screen-
positive women, number of randomised women, number of
women with positive screening tests, number of women with
completed follow-up, and number of women with detected XCIN3
at baseline. We used the following definitions of positive screening
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stests: XASCUS on cytology, X1pgml
 1 HPV DNA on Hybrid
Capture II HPV testing, and the cutoff point reported by the
trialists using PCR GP5þ/6þ HPV testing. In intervention arms
in which both HPV and cytology were used as primary screening
tests, women with at least one of the two tests being positive were
considered screen-positive. We reported on the data from the
Italian phase I RCT separately by age group, as in this RCT
younger women (25–34 years) with abnormal screening tests had a
recommended follow-up procedure different from that of older
women (35–60 years).
For both arms of each RCT, we measured compliance with the
recommended follow-up by calculating the proportion of screen-
positive women who completed the recommended follow-up.
For women referred for colposcopy we considered follow-up
completed after the first colposcopy. For women not referred for
colposcopy, we considered follow-up completed when all recom-
mended repeated tests had been undertaken. Only follow-up with
adequate repeated tests completed before the subsequent screening
round was considered. We used the relative XCIN3 detection as
the indicator of relative sensitivity of HPV screening. The relative
compliance and the 95% CI (Clayton and Hills, 1993), as well as
the relative XCIN3 detection and the 95% CI were calculated for
the intervention group compared with the control group. A linear
association between compliance and XCIN3 detection was
assessed using Pearson’s correlation coefficient. To meet the assu-
mptions for calculating this coefficient, the observed values for
compliance and detection rate were transformed into logarithms.
RESULTS
Impact of the recommended follow-up procedure on
compliance with follow-up
The recommended follow-up procedures varied across RCTs,
including a direct referral for colposcopy, or repeated testing at
6-, 12- or 18-month intervals with colposcopy recommended
only in case of a positive outcome of the repeated testing (Tables 1
and 2). Proportion of women with completed follow-up could be at
least partially determined from all RCTs, with the exception of the
Finnish RCT (Tables 1 and 2).
Compliance with follow-up was dependent on the recommended
follow-up procedure. Typically, around 90% of women complied
with follow-up if they were immediately referred for colposcopy on
the basis of their screening tests alone. In the intervention arms
of the RCTs, this was found for women with XASCUS in Italy
phase I, women with HPVþ/cyt  tests in Italy phase I (35–60
years; Table 1), and HPV-positive women in Italy phase II, Canada,
and India (Table 2). In the control arms of these RCTs, compliance
of around 90% was observed for women with XASCUS in Canada
and India, as well as in Italy phases I and II, in which the majority
of women with ASCUS in the control arms (in seven out of nine
centres) were directly referred for colposcopy.
Follow-up compliance was considerably lower when screen-
positive women were recommended to first undergo repeated
testing for 6 to 18 months after the initial screening. Among
women with an HPVþ/cyt  screening test (Table 1), 55% in the
United Kingdom, 73% in Sweden, and 62% in Italy phase I (25–34
years) complied with repeated testing and a referral for colposcopy
if recommended. In the intervention arm of the Dutch RCT, 58% of
women with either HPVþ/cyt  tests or ASCUS/LSIL complied
with repeated testing. Data on compliance with repeated testing in
the control arm were available from the Dutch RCT only, in which
66% of women with ASCUS/LSIL completed repeated testing.
The data on compliance with follow-up, as published so far,
have been incomplete, and thus the relative compliance with
follow-up could be calculated only from the data obtained from the
Netherlands, Italy phases I and II, Canada, and India (Tables 1 and 2).
Direct referral for colposcopy for screen-positive women in both
arms of these RCTs (Italy phase I (35–60 years), Italy phase II,
Canada, and India) produced non-significant differences in
Table 1 Recommended follow-up, proportion of women with completed follow-up, and relative XCIN3 detection in randomised controlled trials
(RCTs) comparing HPV DNA screening with cytology screening: RCTs with HPV DNA and cytology testing in the intervention arm
United Kingdom The Netherlands Sweden Italy phase 1 Italy phase 1
Age (years) 20–64 29–56 32–38 25–34 35–60
Control arm
XHSIL Colp Colp Colp Colp Colp
LSIL Repeat 6 and 12 Repeat 6 and 18 Repeat/colp Colp Colp
ASCUS Repeat 6 and 12 Repeat 6 and 18 Repeat/colp Colp/repeat 12 Colp/repeat 12
% Follow-up XASCUS NA ASCUS/LSIL: 66.3%
(122/184)
a
NA 93.1% (243/261)
b 89.4% (531/594)
b
Intervention arm with HPV and cytology
XASCUS As control As control As control Colp Colp
HPV+/Cyt  Repeat 12 Repeat 6 and 18 Repeat 12 Repeat 12 Colp
% Follow-up XASCUS NA NA NA 94.3% (496/526)
c 93.1% (832/894)
c
% Follow-up HPV+/Cyt  54.6% (915/1675)
d NA 73.0% (249/341)
e 61.6% (314/510)
f 93.5% (790/845)
c
% Follow-up XASCUS or
HPV+/Cyt 
NA 58.4% (268/459)
a NA 78.2% (810/1036) 93.3% (1622/1739)
Intervention arm vs control arm
Relative % follow-up (95% CI) NA 0.88 (0.71–1.09)
a NA 0.84 (0.73–0.97) 1.04 (0.95–1.15)
Relative detection rate of
XCIN3 (95% CI)
0.97 (0.75–1.25)
((233/18386)/(80/6124))
1.70 (1.15–2.51)
((68/8575)/(40/8580))
1.31 (0.92–1.86)
((72/6257)/(55/6270))
0.70 (0.37–1.34)
((16/6002)/(22/5808))
1.25 (0.78–2.01)
((39/16706)/(31/16658))
Abbreviations: As control¼women followed largely similar follow-up procedures as in the control arm; ASCUS¼Atypical squamous cells of undetermined significance;
CI¼confidence interval; Colp¼referral for colposcopy; Cyt¼cytology; HPV¼human papillomavirus; HSIL¼High-grade squamous intraepithelial lesions; LSIL¼Low-grade
squamous intraepithelial lesions; NA¼not available; Repeat¼repeated testing, with the number indicating the period in months since screening.
aAs reported by Bulkmans et al
(2007), including in the intervention arm HPV+/cyt  women (n¼280) and women with ASCUS/LSIL (n¼179). Compliance was not reported for women with XHSIL.
bWomen who had colposcopy or women with ASCUS with a repeated test and colposcopy, if recommended, in two out of nine centres.
cWomen who had colposcopy.
dWomen with positive repeated HPV tests who had colposcopy (n¼291) and women with a negative repeated HPV test (n¼624).
eWomen with positive repeated tests who
had colposcopy (n¼100) and women with negative repeated tests or a change in type of HPV (n¼149).
fWomen with adequate repeated cytology and HPV testing, who were
either positive on one or both tests and had colposcopy (n¼148) or had both tests negative (n¼166). A total of 14 women had colposcopy immediately after screening; if
these women are considered to have completed the follow-up, the proportion becomes 64.3% (328/510).
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scompliance with follow-up between the two arms. In the Nether-
lands, compliance with repeated testing was non-significantly
lower in the intervention arm than in the control arm (0.88; 95%
CI, 0.71–1.09). In Italy phase I (25–34 years), in which women
with HPVþ/cyt  tests were recommended repeated testing,
whereas most women with XASCUS were directly referred for
colposcopy, compliance in the intervention arm was significantly
lower than in the control arm (0.84; 95% CI, 0.73–0.97). Therefore,
with the exception of the latter RCT, the compliance with follow-up
in the intervention arm was similar to the compliance in the
control arm.
The effect of completeness of follow-up on screening
sensitivity
The eight RCTs showed surprisingly heterogeneous outcomes in
terms of extra XCIN3 detection with HPV testing. Data on relative
XCIN3 detection were available from all European RCTs (Tables 1
and 2). Two of these estimates were non-significantly below unity:
UK 0.97 (95% CI, 0.75–1.25) and Italy phase II (25–34 years) 0.70
(95% CI, 0.37–1.34). Three estimates were statistically insignif-
icantly increased: Sweden 1.31 (95% CI, 0.92–1.86), Italy phase I
(35–60 years) 1.25 (95% CI, 0.78–2.01), and Finland 1.22 (95% CI,
0.78–1.92), whereas two estimates were statistically significantly
increased: the Netherlands 1.70 (95% CI, 1.15–2.51) and Italy
phase II 2.26 (95% CI, 1.42–3.58). The Canadian and Indian RCTs
reported relative XCIN2 detection only: 1.57 (95% CI, 0.76–3.24)
and 0.87 (95% CI, 0.74–1.01), respectively.
Could this variation in relative XCIN3 detection be explained
by a variation in compliance with follow-up? As explained above,
the complete compliance data were available from the Dutch,
Italian, Canadian, and Indian RCTs only, whereas data on XCIN3
detection were available from the European RCTs only. Relative
compliance and relative XCIN3 detection could therefore only be
compared for the Dutch and Italian data (Tables 1 and 2). The
correlation coefficient was 0.56 (P¼0.44), suggesting a modest and
non-significant correlation.
Given this paucity of complete data, we additionally considered
only the data on the absolute level of compliance among women
with HPVþ/cyt  or HPVþ tests, which were available for all
European RCTs except of the Finnish. Using these data, we
calculated the correlation between compliance with follow-up for
HPVþ/cyt  (Sweden, United Kingdom, Italy phase I (25–34
years), and the Netherlands; Table 1) or HPVþ women (Italy
phase II; Table 2), and the relative XCIN3 detection. As a proxy
for the compliance of HPVþ/cyt  women in the Netherlands,
we used the 58% compliance for combined ASCUS/LSIL and
HPVþ/cyt . The correlation coefficient was 0.48 (P¼0.33) in this
case, that is, modest and non-significant correlation.
DISCUSSION
Compliance with recommended follow-up
Although compliance with immediate referral for colposcopy was
high (B90%) in all RCTs with reported data, low compliance with
repeated testing was common in all RCTs recommending this
procedure. Among HPVþ/cyt  women, 55% completed repeated
testing in the UK RCT, 58% in the Dutch RCT, 62% in the Italian
phase I RCT (25–34 years), and 73% in the Swedish RCT.
Furthermore, in the control arm of the Dutch RCT, a comparable
proportion, only 66%, of women completed the recommended
repeated testing.
Our estimates of absolute compliance may have been affected by
incomplete reporting of the RCT data. The United Kingdom,
Italian, and Dutch RCTs did not systematically report the number
of women with inadequate repeated tests. Because we assumed in
such cases that all repeated tests were adequate, compliance with
follow-up in terms of being ‘properly investigated’ may have been
slightly overestimated. For the Dutch RCT, we could not
determine, from the original report, whether the number with
‘completed repeat testing’ (Bulkmans et al, 2007) accounted for
women undergoing colposcopy if recommended, while for Italy
phase I RCT (25–34 years) it was not reported how many women
with ASCUS with a recommendation for repeated testing did have
repeated testing. In both cases, we assumed that all women
completed the recommended follow-up tests.
For women testing HPVþ/cyt  in the UK RCT, our estimate of
compliance with follow-up, 54.6%, differed from the estimate
reported earlier, 41.2% (Sasieni et al, 2009). The latter was
calculated as 62.1% (the proportion of HPVþ/cyt  women
retested at 12 months)  66.3% (proportion of women with
persistent HPV on retest who had colposcopy). It did not include
all women for whom the repeated test at 12 months was negative,
and who were therefore ‘properly investigated’ (Sasieni et al, 2009)
according to the protocol without undergoing colposcopy. Our
estimate was additionally higher, although to a minor degree,
Table 2 Recommended follow-up, proportion of women with completed follow-up, and relative XCIN3 detection in randomised controlled trials
comparing HPV DNA screening with cytology screening: RCTs with stand-alone HPV testing in the intervention arm
Italy phase II Finland Canada India
Age (years) 25–60 30–60 30–69 30–59
Control arm
XHSIL Colp Colp Colp Colp
LSIL Colp Colp Colp Colp
ASCUS Colp/repeat 12 Repeat 12 Colp Colp
% Follow-up XASCUS 87.6% (723/825)
a NA 91.4% (138/151)
b 87.9% (1570/1787)
b
Intervention arm with stand-alone HPV
HPV+ Colp LSIL+: Colp; other: repeat 12 Colp Colp
% Follow-up HPV+ 93.6% (1812/1936)
b NA 90.7% (284/313)
b 89.1% (2505/2812)
b
Intervention arm vs control arm
Relative % follow-up (95% CI) 1.07 (0.98–1.16) NA 0.99 (0.81–1.22) 1.01 (0.95–1.08)
Relative detection rate of XCIN3 (95% CI) 2.26 (1.42–3.58)
((59/24661)/(26/24535))
1.22 (0.78–1.92)
((42/35837)/(34/35500))
1.57 (0.76–3.24)
((19/5095)/(12/5059))
c
0.87 (0.74–1.01)
((318/27192)/(345/25549))
c
Abbreviations: CI¼confidence interval; Colp¼referral for colposcopy; HPV¼human papillomavirus; NA¼not available; Repeat¼repeated testing, with the number indicating
the period in months since screening.
aWomen who had colposcopy or women with ASCUS with a repeated test and colposcopy, if recommended, in two out of nine centres.
bWomen who had colposcopy.
cRelative detection of XCIN2; XCIN3 not reported separately.
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sbecause we accounted for women with a positive repeated HPV test
at 12 months, who were given a choice to have a repeated HPV
test at 24 months, and did not need to undergo colposcopy if
they cleared the HPV infection by 24 months. This information
was only provided in a later publication from the UK RCT
(Kitchener et al, 2009b).
Compliance with follow-up and sensitivity of
HPV screening
In assessing the correlation between compliance and XCIN3
detection, much emphasis has thus far been placed on the UK RCT.
In this RCT, women with HPVþ/cyt  screening tests were
recommended repeated testing after 12 months, whereas women
with ASCUS/LSIL were recommended repeated testing after 6
months. It was, however, not possible to independently determine
whether this difference in the recommended time interval affected
compliance and consequently the lack of extra detection of
XCIN3, as no follow-up data were reported for the control arm,
nor have data for a similar group been reported in the routine
screening statistics (The NHS Information Centre, Workforce and
Facilities Team, 2009).
So far, virtually complete data on compliance have only been
reported from the Dutch and Italian RCTs, with an estimated
correlation of 0.56 (P¼0.44) between compliance with follow-up
and measured sensitivity of HPV screening. We used the data from
the first reports on baseline data from the Italian RCTs (Ronco
et al, 2006a, 2006b, 2008). The XCIN3 detection was higher in a
second report on baseline data (Ronco et al, 2010), but this report
did not include updated data on compliance with follow-up.
Compliance was close to 90% in both arms of the Canadian and
Indian RCTs. However, these RCTs reported only the relative
XCIN2 detection, being 1.57 (95% CI, 0.76–3.24) and 0.87 (95%
CI, 0.74–1.01), respectively. Whereas the relative XCIN3 detection
could theoretically be above unity in the Canadian RCT, although
not statistically significantly, this seems highly unlikely for the
Indian RCT. The available data thus indicate a considerable
variation in the relative XCIN3 detection even in RCTs with good
compliance with follow-up in both arms.
Owing to the lack of completely reported compliance data
from all European RCTs, we instead investigated the correlation
between the absolute level of completeness of follow-up among
HPVþ/cyt  or HPVþ women and the relative XCIN3 detection.
There was a considerable variation in this compliance—from 94%
in Italy phase II to 55% in the United Kingdom—but this was not
reflected in a corresponding variation in XCIN3 detection,
resulting in a low correlation coefficient of 0.48 (P¼0.33).
However, in the interpretation of these outcomes, the paucity of
the available data should be taken into account. To better elucidate
the impact of compliance on the outcome of HPV screening, it is
strongly recommended that comprehensive compliance data are
published from all RCTs. Taken together, however, at present there is
scant evidence from published reports to support the by now widely
accepted view that the measured relative sensitivity of HPV screening
is a simple reflection of relative compliance with follow-up.
Appropriateness of adjustment for incomplete follow-up
If adjustment for incomplete follow-up is applied to RCT data,
both arms should undergo adjustment so as to not bias the
comparison. However, previously, only adjustment for women in
the intervention arm who had an HPVþ/cyt  test was applied
(Sasieni et al, 2009). Furthermore, the CIN detection in
colposcopically investigated women with repeated positive tests
cannot be generalised to women with a positive screening test and
no colposcopy. The latter group included women who did not need
to undergo colposcopy, because their repeated tests were negative.
The prevalence of CIN in these women may be substantially lower
than in women with repeated positive HPV tests. Therefore, the
outcomes of the reanalysis of the UK RCT data as carried out
previously may have been biased.
Adjustment might, moreover, be problematic even when an
unbiased estimate can be made. The European RCTs were
undertaken to evaluate HPV screening in real-life settings. In this
situation, an upwards correction of CIN detection due to
incomplete compliance would be appropriate only if the level
of compliance in the RCT was considerably lower than the level of
compliance attainable in everyday screening practice. If, on the
other hand, compliance with follow-up observed in the RCT is
comparable with that attainable in the screening programme, CIN
detection in the RCT can be seen as an acceptable estimate for the
expected CIN detection. In this case, any further adjustment would
lead to an artificial overestimation of XCIN3 detection and would
therefore affect the expected outcome of a shift from cytology to
HPV screening.
CONCLUSION
Incomplete compliance with recommended follow-up procedures
for women with positive screening tests was found in several RCTs
comparing HPV screening with cytology screening. Only some of
the trials found the detection of XCIN3 cases to be significantly
increased in the HPV-screening arm. Follow-up compliance
was dependent on the recommended follow-up procedures, but
there was scant evidence of an unequivocal relationship between
follow-up compliance and XCIN3 detection. Adjustment of
measured CIN detection on the basis of compliance data may
not always be justifiable, and if adjustment is made, it should be
used very judiciously.
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